Donald Santel

Donald Santel General Information

Biography

Mr. Donald Santel serves as Chairman at Tentarix Biotherapeutics.He serves as Board Member BioAge Labs. He serves as Board Member at Aerovate Therapeutics. He served as Executive Chairman at Adicet Bio. He served as a Board Member of Abilitech Medical. He was a Board Member of Hyperion Therapeutics, where he served as Chief Executive Officer and President. served as Executive Chairman of Adicet Bio, Inc., a private allogeneic cell therapy oncology company, from October 2017 through its business combination with resTORbio, Inc. in September 2020. From March 2018 through April 2019, Mr. Santel also served as Adicet Bio's interim Chief Executive Officer. He previously served as Chief Executive Officer of Hyperion Therapeutics, a public biopharmaceutical company, from June 2008 until the sale of the company to Horizon Pharma in May 2015 and was a member of Hyperion's board of directors from March 2007 through the company's sale. Previously, Mr. Santel was a co-founder, a member of the board of directors, and the Chief Executive Officer of CoTherix, Inc., from January 2000 through its sale to Actelion in January 2007. Prior to joining CoTherix, Mr. Santel was employed by several medical device companies, including Cardiac Pathways Corporation (acquired by Boston Scientific) and Medtronic, Inc. He has served as chairman and independent director of Ocelot Bio a private biopharmaceutical company, since June 2021, and as chairperson of Oyster Point Pharma, Inc., a publicly traded biopharmaceutical company, since July 2021. Mr. Santel has also served as an independent director of Consonance-HFW Acquisition Corporation from November 2020 through the completion of its business combination with Surrozen, Inc., in August 2021. Mr. Santel previously served on the board of directors and the audit and compensation committees of Anthera Pharmaceuticals, Inc., and as a director of ChemGenex Pharmaceuticals, Inc.